Article
Oncology
Daniele Lavacchi, Giandomenico Roviello, Elisa Giommoni, Lorenzo Dreoni, Silvia Derio, Marco Brugia, Amedeo Amedei, Serena Pillozzi, Lorenzo Antonuzzo
Summary: The addition of aflibercept to FOLFIRI has shown to enhance survival in mCRC patients who have progressed after standard oxaliplatin-based regimens. A retrospective study on real-world clinical practice found that aflibercept-FOLFIRI is a feasible second-line treatment, with PFS in first-line therapy >12 months being the key predictive marker for improved survival.
Article
Oncology
Elena Elez, Maria Auxiliadora Gomez-Espana, Cristina Gravalos, Pilar Garcia-Alfonso, Maria Jose Ortiz-Morales, Ferran Losa, Inmaculada Ales Diaz, Begona Grana, Marta Toledano-Fonseca, Manuel Valladares-Ayerbes, Eduardo Polo, Mercedes Salgado, Eva Martinez de Castro, Maria Jose Safont, Antonieta Salud, Ana Ruiz-Casado, Josep Tabernero, Maria del Carmen Riesco, Antonio Rodriguez-Ariza, Enrique Aranda
Summary: This study supports the benefits of aflibercept plus FOLFIRI in treating mCRC patients, with VEGF-A levels below 1941pg/mL potentially serving as a biomarker to predict better outcomes. ACE levels did not show significant differences in treatment efficacy.
BRITISH JOURNAL OF CANCER
(2022)
Article
Medicine, Research & Experimental
M. Toledano-Fonseca, M. A. Gomez-Espana, E. Elez, C. Gravalos, P. Garcia-Alfonso, R. Rodriguez, F. Losa, I. Ales Diaz, B. Grana, M. Valladares-Ayerbes, M. V. Garcia-Ortiz, E. Polo, M. Salgado, F. Rivera, M. J. Safont, A. Salud, A. Ruiz-Casado, J. M. Tabernero, M. C. Riesco, A. Rodriguez-Ariza, E. Aranda
Summary: This study examined the profiles of circulating microRNAs (miRNAs) in metastatic colorectal cancer patients and found that certain miRNAs, such as hsa-miR-33b-5p, could serve as valuable biomarkers for predicting response to therapy and disease progression. Combining the levels of circulating VEGF-A with miR-33b-5p further improved the stratification of patients.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Seung-Hoon Beom, Jong Gwang Kim, Seung Hyuk Baik, Seong Hoon Shin, Inkeun Park, Young Suk Park, Myung-Ah Lee, Soohyeon Lee, So-Yeon Jeon, Sae-Won Han, Myoung Hee Kang, Jisu Oh, Jin Soo Kim, Jin Young Kim, Mi Sun Ahn, Dae Young Zang, Byung-Noe Bae, Hong Jae Jo, Hee Kyung Kim, Jung-Han Kim, Ji Ae Yoon, Dong Han Kim
Summary: The study aimed to evaluate the safety and effectiveness of aflibercept in combination with FOLFIRI regimen in Korean patients with metastatic colorectal cancer. The results showed that the treatment was effective and had an acceptable safety profile in daily clinical practice.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jun Watanabe, Tetsuji Terazawa, Shiho Yamane, Hirotaka Kazama, Hiroyuki Uetake, Takayuki Yoshino
Summary: This study evaluated the safety and effectiveness of aflibercept with 5-fluorouracil/levofolinate/irinotecan in Japanese patients with mCRC in a real-world clinical setting. The results showed that there were no new risks associated with aflibercept and its effectiveness in second-line treatment was consistent with previous reports.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Pu Ge, Chunyan Han, Abudurousuli Reyila, Diyue Liu, Wenying Hong, Jiaxin Liu, Jinzi Zhang, Xiao Han, Xialei Li, Mengjie Huang, Siyuan Fan, Ayidana Kaierdebieke, Xiaoyu Wu, Xiaolu Huang, Weirui Guo, Siyu Liu, Ying Bian
Summary: This study systematically reviewed the risk of antiangiogenic adverse events in patients with metastatic colorectal cancer receiving aflibercept plus chemotherapy. The results showed an increased risk of antiangiogenic adverse events with the use of aflibercept compared to controls. However, further studies are needed to confirm this association.
Article
Oncology
Jinchul Kim, Hana Kim, Jung Yong Hong, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Seung Tae Kim
Summary: This study identified and validated significant prognostic factors for progression-free survival with aflibercept plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Factors such as response to first-line treatment, tumor location, CEA level, and RAS/RAF mutation status were found to be important predictors for both progression-free survival and overall survival outcomes.
Article
Oncology
H. Jo, M-S Lee, Y-P Lee, H. Kim, J. Y. Hong, J. Lee, S. H. Park, J. O. Park, Y. S. Park, H. Y. Lim, W. K. Kang, S. T. Kim
Summary: This study compared the efficacy and safety of FOLFIRI plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients. The results showed no significant differences in tumor response rate and survival between the two treatment groups, but hypertension of grade 3 or more was more frequent in the FOLFIRI-aflibercept group.
Article
Oncology
Cecile Torregrosa, Simon Pernot, Pauline Vaflard, Audrey Perret, Christophe Tournigand, Violaine Randrian, Solene Doat, Cindy Neuzillet, Valerie Moulin, Morgane Stouvenot, Gael Roth, Tiffany Darbas, Benjamin Auberger, Tiphaine Godet, Marion Jaffrelot, Aurelien Lambert, Olivier Dubreuil, Cassandre Gluszak, Alice Bernard-Tessier, Anthony Turpin, Lola-Jade Palmieri, Olivier Bouche, Gael Goujon, Thierry Lecomte, David Sefrioui, Christophe Locher, Lucien Grados, Pauline Gignoux, Stephanie Trager, Elise Nassif, Angelique Saint, Pascal Hammel, Cedric Lecaille, Mathilde Bureau, Marine Perrier, Damien Botsen, Vincent Bourgeois, Julien Taieb, Edouard Auclin
Summary: In second-line treatment, for patients with metastatic colorectal cancer, the combination of FOLFIRI and bevacizumab is associated with longer overall survival and progression-free survival compared to the combination of FOLFIRI and aflibercept.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Nieves Martinez-Lago, Soledad Cameselle Garcia, Beatriz Alonso de Castro, Martin Gomez-Randulfe Rodriguez, Marta Carmona Campos, Paula Gonzalez Villarroel, Mercedes Salgado Fernandez, Juan C. De la Camara Gomez, Carlos Romero Reinoso, Antia Cousillas Castineiras, Jose Carlos Mendez Mendez, Yolanda Vidal Insua, Ana Fernandez-Montes
Summary: The study demonstrates the efficacy of FA in elderly patients, with a need for careful consideration of side effects and dose adjustments in those over 75 years old. It also highlights the predictive value of hypertension for treatment efficacy.
Article
Oncology
Alessandro Ottaiano, Stefania Scala, Mariachiara Santorsola, Anna Maria Trotta, Crescenzo D'Alterio, Luigi Portella, Ottavia Clemente, Anna Nappi, Nicoletta Zanaletti, Alfonso De Stefano, Antonio Avallone, Vincenza Granata, Carmen Notariello, Amalia Luce, Angela Lombardi, Carmine Picone, Antonella Petrillo, Francesco Perri, Fabiana Tatangelo, Annabella Di Mauro, Vittorio Albino, Francesco Izzo, Daniela Rega, Ugo Pace, Massimiliano Di Marzo, Paolo Chiodini, Gianfranco De Feo, Paola Del Prete, Gerardo Botti, Paolo Delrio, Michele Caraglia, Guglielmo Nasti
Summary: The study aims to compare the efficacy of second-line treatments with FOLFIRI/bevacizumab beyond progression versus FOLFIRI/aflibercept in mRAS mCRC patients, and to identify angiogenic factors' patterns that could assist oncologists in applying anti-angiogenic strategies more effectively.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Oncology
Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grunberger, Hans G. Derigs, Mark-Oliver Zahn, Christine Geffriaud-Ricouard, Max Gueldner, Christine Windemuth-Kieselbach, Stefanie Pederiva, Pierre Bohanes, Felicitas Scholten, Gudrun Piringer, Josef Thaler, Roger von Moos
Summary: In patients with metastatic colorectal cancer, treatment with aflibercept plus FOLFIRI can maintain quality of life, increase objective tumor response rate, and retain activity regardless of sex, RAS status, and prior EGFR-I therapy.
Article
Oncology
Michio Kimura, Eiseki Usami, Hitomi Teramachi, Tomoaki Yoshimura
Summary: This study found that, as a third-line treatment for metastatic colorectal cancer, F-RAM/AFL has a higher overall survival rate compared to TAS-102, although the risk of adverse events should be considered.
ANTICANCER RESEARCH
(2021)
Review
Oncology
Julian E. Riedesser, Matthias P. Ebert, Johannes Betge
Summary: This review summarizes recent advances in personalized treatment for patients with metastatic colorectal cancer. We provide an overview of current multimodal therapy and explain novel immunotherapy and targeted therapy approaches in detail. We emphasize clinically relevant therapies and provide recommendations for clinical practice.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Martina Catalano, Daniele Lavacchi, Elisa Giommoni, Sonia Shabani, Alessia Guidolin, Marco Brugia, Roberto Petrioli, Monica Ramello, Serena Pillozzi, Lorenzo Antonuzzo, Giandomenico Roviello
Summary: This study indicates that higher pretreatment serum sodium levels are associated with improved outcomes in metastatic colorectal cancer patients receiving aflibercept and FOLFIRI.
Article
Oncology
Marta Espanol-Rego, Carlos Fernandez-Martos, Elena Elez, Carles Foguet, Leire Pedrosa, Nuria Rodriguez, Ana Ruiz-Casado, Estela Pineda, Joan Cid, Raquel Cabezon, Helena Oliveres, Miquel Lozano, Angels Gines, Angeles Garcia-Criado, Juan Ramon Ayuso, Mario Pages, Miriam Cuatrecasas, Ferran Torres, Timothy Thomson, Marta Cascante, Daniel Benitez-Ribas, Joan Maurel
Summary: This study investigated the potential of Avelumab combined with ADC vaccine as a treatment for MSS mCRC patients. The results showed that the combination therapy was safe and well tolerated, but had limited clinical activity. Additionally, the study found a post-therapy metabolic rewiring, which could represent novel immunotherapy-induced tumor vulnerabilities.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
David K. Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Mohamed, Irene Monahan, David J. Clark, Nicholas Eckersley, Henry M. Staines, Elisabetta Groppelli, Sanjeev Krishna, Martin Mayora-Neto, Nigel Temperton, Charlotte Fribbens, David Watkins, Naureen Starling, Ian Chau, David Cunningham, Sheela Rao
Summary: The study evaluated the prevalence of neutralizing antibodies in 152 gastrointestinal cancer patients receiving chemotherapy after SARS-CoV-2 vaccination, finding that despite the immunosuppressive effects of chemotherapy, two doses of vaccines can still induce a protective immune response in patients undergoing treatment.
Article
Medicine, General & Internal
Maria Romero-Elias, Alejandro Alvarez-Bustos, Blanca Cantos, Constanza Maximiano, Miriam Mendez, Marta Mendez, Cristina G. de Pedro, Silvia Rosado-Garcia, Antonio J. Sanchez-Lopez, David Garcia-Gonzalez, Hector Cebolla-Boado, Ana Ruiz-Casado
Summary: Physical fitness is an important factor in predicting mortality. This study focused on breast cancer survivors and found that C-reactive protein (CRP) is associated with various components of physical fitness, indicating poor physical condition in these survivors. Additionally, insulin was associated with cardiorespiratory fitness and gait speed. These findings have implications for healthcare professionals to recommend lifestyle changes to improve the physical condition and cardiovascular risk of breast cancer survivors.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Susanna Slater, Annette Bryant, Hsiang-Chi Chen, Ruwaida Begum, Isma Rana, Maria Aresu, Clare Peckitt, Oleg Zhitkov, Retchel Lazaro-Alcausi, Victoria Borja, Rachel Powell, David Lowery, Michael Hubank, Thereasa Rich, Gayathri Anandappa, Ian Chau, Naureen Starling, David Cunningham
Summary: This study aims to determine whether a de-escalation strategy using ctDNA to guide adjuvant chemotherapy is as effective as standard of care chemotherapy in patients with resected colorectal cancer. The primary endpoint is the difference in disease-free survival at 3 years between the trial arms. The study has the potential to reduce unnecessary chemotherapy and associated toxicity.
Article
Oncology
David K. Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starling
Summary: A retrospective study was conducted in a high volume cancer center in London to evaluate the impact of implementing DPYD variant testing for gastrointestinal cancer patients. The results showed that DPYD genotype testing prior to fluoropyrimidine chemotherapy ensured patient safety and the incidence of adverse events was similar to wild-type carriers.
Article
Medicine, General & Internal
Mairead G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Summary: This study compared the efficacy of liposomal irinotecan/5-FU/folinic acid and docetaxel in the treatment of PD-EP-NEC as second-line therapy. The results showed that liposomal irinotecan/5-FU/folinic acid achieved a 6-month progression-free survival rate of 29.6%, while docetaxel did not meet the primary endpoint. Liposomal irinotecan/5-FU/folinic acid demonstrated manageable toxicity and maintained quality of life.
Meeting Abstract
Oncology
J. Mencel, F. Turkes, L. Barber, B. Challoner, M. Buzzetti, A. Tran, H. Chen, N. McCafferty, A. Woolston, R. Crux, I. Rana, J. Thomas, V. Borja, R. Begum, E. Johnston, N. Fotiadis, M. Terlizzo, S. Rao, I. Chau, D. Cunningham, M. Gerlinger, N. Starling
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Do-Youn Oh, Maria Alsina Maqueda, David I. Quinn, Peter J. O'Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K. Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P. Dean, Hendrik-Tobias Arkenau
Summary: This study evaluated the safety and efficacy of Ibrutinib combined with companion drugs for RCC, GC, and CRC, but did not observe clinically significant increases in efficacy compared to historical controls.
Article
Oncology
Monica Castellanos-Montealegre, Fernando Rivera-Theruel, Virginia Garcia-Coll, Natalia Rioja-Collado, Lucia Gil-Herrero, Sara Lopez-Tarruella, Maria Montealegre Sanz, Sara Cerezo Gonzalez, Antonio Fernandez Aramburo, Ana Ruiz-Casado, Rebecca Laundos, Soraya Casla-Barrio
Summary: The lockdown measures during the COVID-19 pandemic have had an impact on physical activity levels among young adults with cancer in Spain. There was a decrease in physical activity during the lockdown, but a significant increase was observed after the lockdown. Quality of life and fatigue levels were worse during the lockdown, and while physical activity levels partially recovered after the lockdown, quality of life and fatigue levels remained affected.
Meeting Abstract
Oncology
Mairead Geraldine McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard Hubner, Juan W. Valle
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Susanna Slater, Annette Bryant, Maria Aresu, Ruwaida Begum, Hsiang-Chi Chen, Clare Peckitt, Retchel Lazaro-Alcausi, Paul Carter, Gayathri Anandappa, Shelize Khakoo, Graham Branagan, Nicol George, Muti Abulafi, Sarah Duff, Nicholas West, Leslie Bucheit, Thereasa A. Rich, Ian Chau, Naureen Starling, David Cunningham
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Avani Athauda, Tatiany Silveira, Thomas Lund, Katharina von Loga, Benjamin Challoner, Isma Rana, Janet Thomas, Naureen Starling, Ian Chau, Sheela Rao, David J. Watkins, David Cunningham, Marco Gerlinger
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Anderley Gordon, Benjamin Challoner, Avani Athauda, Andrew Woolston, Sonia Mansukhani, Matt Dunstan, Nikoletta Petrou, Komel Khabra, Retchel Lazaro-Alcausi, Richard Crux, Victoria Borja, Ruwaida Begum, Isma Rana, Sheela Rao, Sacheen Kumar, David Cunningham, Ian Chau, Naureen Starling, M. Asif Chaudry, Marco Gerlinger
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Ken Kato, Jaffer A. Ajani, Yuichiro Doki, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Freitas Melro Braghiroli, Eva Holtved, Mariela A. Blum Murphy, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Ian Chau, Yuko Kitagawa
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Benjamin R. Challoner, Andrew Woolston, David Lau, Marta Buzzetti, Caroline Fong, Louise J. Barber, Gayathri Anandappa, Richard Crux, Ioannis Assiotis, Kerry Fenwick, Ruwaida Begum, Dipa Begum, Tom Lund, Nanna Sivamanoharan, Harold B. Sansano, Melissa Domingo-Arada, Amina Tran, Hardev Pandha, David Church, Bryony Eccles, Richard Ellis, Stephen Falk, Mark Hill, Daniel Krell, Nirupa Murugaesu, Luke Nolan, Vanessa Potter, Mark Saunders, Kai-Keen Shiu, Sebastian Guettler, James L. Alexander, Hector Lazare-Iglesias, James Kinross, Jamie Murphy, Katharina von Loga, David Cunningham, Ian Chau, Naureen Starling, Juan Ruiz-Banobre, Tony Dhillon, Marco Gerlinger
Summary: MMRd CRCs have high mutation burdens and pervasive ITH, but driver mutations show a clear hierarchy. Immune evasion (IE) drivers are mainly subclonal and show parallel evolution. IE drivers and T cell infiltrates coevolve. PD-L1 expression correlates with T cell density but is associated with loss of CDX2 expression, leading to a higher recurrence risk in MMRd CRCs.
JOURNAL OF PATHOLOGY
(2023)